61405
document
Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders : a multisite randomized clinical trial . IMPORTANCE The finding of factors that differentially predict the likelihood of response to placebo over that of an active drug could have a significant impact on study design in this population . OBJECTIVE To identify possible nonspecific , baseline predictors of response to intervention in a large randomized clinical trial of children and adolescents with autism spectrum disorders . DESIGN , SETTING , AND PARTICIPANTS Randomized clinical trial of citalopram hydrobromide for children and adolescents with autism spectrum disorders and prominent repetitive behavior . Baseline data at study entry were examined with respect to final outcome to determine if response predictors could be identified . A total of 149 children and adolescents 5 to 17 years of age ( mean [ SD ] age , 9.4 [ 3.1 ] years ) from 6 academic centers were randomly assigned to citalopram ( n = 73 ) or placebo ( n = 76 ) . Participants had autistic disorder , Asperger syndrome , or pervasive developmental disorder , not otherwise specified ; had illness severity ratings that were moderate or more than moderate on the Clinical Global Impression-Severity scale ; and scored moderate or more than moderate on compulsive behaviors measured with the modified Children 's Yale-Brown Obsessive-Compulsive Scale . INTERVENTIONS Twelve weeks of treatment with citalopram ( 10 mg/5 mL ) or placebo . The mean ( SD ) maximum dose of citalopram was 16.5 ( 6.5 ) mg by mouth daily ( maximum dose , 20 mg/d ) . MAIN OUTCOMES AND MEASURES A positive response was defined as having a score of at least much improved on the Clinical Global Impression-Improvement scale at week 12 . Baseline measures included demographic ( sex , age , weight , and pubertal status ) , clinical , and family measures . Clinical variables included baseline illness severity ratings ( the Aberrant Behavior Checklist , the Child and Adolescent Symptom Inventory , the Vineland Adaptive Behavior Scales , the Repetitive Behavior Scale-Revised , and the Children 's Yale-Brown Obsessive-Compulsive Scale ) . Family measures included the Caregiver Strain Questionnaire . RESULTS Several baseline predictors of response were identified , and a principal component analysis yielded 3 composite measures ( disruptive behavior , autism/mood , and caregiver strain ) that significantly predicted response at week 12 . Specifically , participants in the placebo group were significantly less likely than participants in the citalopram group to respond at week 12 if they entered the study more symptomatic on each of the 3 composite measures , and they were at least 2 times less likely to be responders . CONCLUSIONS AND RELEVANCE This analysis suggests strategies that may be useful in anticipating and potentially mitigating the nonspecific response in randomized clinical trials of children and adolescents with autism spectrum disorders . TRIAL REGISTRATION clinicaltrials.gov Identifier : NCT00086645 .
61406
Intervention_Control
placebo
61407
Intervention_Pharmacological
citalopram hydrobromide
61408
Intervention_Pharmacological
citalopram
61409
Intervention_Control
placebo
61410
Intervention_Pharmacological
citalopram
61411
Intervention_Control
placebo
61412
Outcome_Other
response to intervention
61413
Outcome_Other
Clinical Global Impression-Improvement scale
61414
Outcome_Physical
the Aberrant Behavior Checklist
61415
Outcome_Physical
the Child and Adolescent Symptom Inventory
61416
Outcome_Physical
the Vineland Adaptive Behavior Scales , the Repetitive Behavior Scale-Revised
61417
Outcome_Physical
the Children 's Yale-Brown Obsessive-Compulsive Scale
61418
Outcome_Other
Caregiver Strain Questionnaire
61419
Outcome_Mental
( disruptive behavior , autism/mood , and caregiver strain )
61420
Participant_Condition
children and adolescents with autism spectrum disorders and prominent repetitive behavior .